Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GMAB
GMAB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GMAB News
BioNJ Elects New Board Officers and Members
3d ago
Yahoo Finance
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
Newsfilter
Alphabet and Nvidia Lead AI Investment Wave, AbbVie and IBKR Show Long-Term Resilience
Jan 22 2026
NASDAQ.COM
2026 Investment Outlook: Four Stocks with Compounding Potential
Jan 22 2026
Fool
Genmab's DARZALEX Sales Reach $14.35 Billion in 2025, Continuing Growth
Jan 21 2026
NASDAQ.COM
Genmab Reports $14.35 Billion in DARZALEX® Global Sales for 2025
Jan 21 2026
Globenewswire
Genmab Reports EPCORE DLBCL-1 Trial Results, Survival Rate Not Statistically Significant
Jan 20 2026
Benzinga
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
Jan 20 2026
Yahoo Finance
AbbVie and Genmab Release EPCORE DLBCL-1 Trial Results, Epcoritamab Significantly Improves Progression-Free Survival
Jan 17 2026
NASDAQ.COM
Genmab (GMAB) Reports Epcoritamab Trial Shows Progression-Free Survival Improvement
Jan 16 2026
stocktwits
Genmab's Epcoritamab Extends Survival in DLBCL Patients, Stock Drops 7%
Jan 16 2026
seekingalpha
Genmab Reports EPCORE DLBCL-1 Trial Results, Significant PFS Improvement Observed
Jan 16 2026
Businesswire
Genmab Reports EPCORE DLBCL-1 Trial Results, Significant PFS Improvement
Jan 16 2026
Globenewswire
Genmab Partners with Anthropic to Enhance Data Processing Efficiency
Jan 07 2026
Benzinga
Genmab Partners with Anthropic to Enhance R&D Efficiency
Jan 07 2026
Newsfilter
Show More News
